Gewinn- und Verlustrechnung von Bristol-Myers Squibb Company

BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Advisors Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 1,029,843 shares of the biopharmaceutical company's stock, valued at approximately $59,340,000. Advisors Capital Management LLC owned about

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery.

Bell and Brown Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb Company (NYSE: BMY) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 42,598 shares of the biopharmaceutical company's stock, valued at approximately $2,455,000. A number of other

Abacus FCF Advisors LLC acquired a new stake in shares of Bristol Myers Squibb Company (NYSE: BMY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 227,584 shares of the biopharmaceutical company's stock, valued at approximately $13,113,000. Bristol Myers Squibb comprises approximately

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling, yet each company's standalone strength deserves closer scrutiny. Overall, AZN and BMY occupy leading positions in the cancer and immune-mediated inflammatory diseases markets. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the rival.